Advances in Modular Control of CAR-T Therapy with Adapter-mediated CARs

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2022 May 26

PMID 35618140

Authors

Amelia C McCue

Zhiyuan Yao

Brian Kuhlman

Affiliations

Soon will be listed here.

Abstract

Protein engineering has contributed to successes in the field of T cell-based immunotherapy, including chimeric antigen receptor (CAR) T cell therapy. CAR T cell therapy has become a pillar of cancer immunotherapy, demonstrating clinical effectiveness against B cell malignancies by targeting the B cell antigen CD19. Current gene editing techniques have limited safety controls over CAR T cell activity, which presents a hurdle for control of CAR T cells in patients. Alternatively, CAR T cell activity can be controlled by engineering CARs to bind soluble adapter molecules that direct the interaction between the CAR T cell and target cell. The flexibility in this adapter-mediated approach overcomes the rigid specificity of traditional CAR T cells to allow targeting of multiple cell types. Here we describe adapter CAR T technologies and how these methods emphasize the growing role of protein engineering in the design of programmable tools for T cell therapies.

Citing Articles

Application of novel CAR technologies to improve treatment of autoimmune disease.

Cheever A, Kang C, ONeill K, Weber K Front Immunol. 2024; 15:1465191.

PMID: 39445021 PMC: 11496059. DOI: 10.3389/fimmu.2024.1465191.

CAR T-cells for pediatric solid tumors: where to go from here?.

Trautmann T, Yakobian N, Nguyen R Cancer Metastasis Rev. 2024; 43(4):1445-1461.

PMID: 39317919 PMC: 11554711. DOI: 10.1007/s10555-024-10214-6.

UniCAR T-Cell Potency-A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?.

Boutier H, Loureiro L, Hoffmann L, Arndt C, Bartsch T, Feldmann A Int J Mol Sci. 2024; 25(13).

PMID: 39000348 PMC: 11241561. DOI: 10.3390/ijms25137242.

CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy.

Cui Y, Luo M, Gu C, He Y, Yao Y, Li P Biophys Rep. 2024; 9(5):279-297.

PMID: 38516299 PMC: 10951476. DOI: 10.52601/bpr.2023.230020.

The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments.

Chen T, Deng J, Zhang Y, Liu B, Liu R, Zhu Y Mol Cancer. 2024; 23(1):53.

PMID: 38468291 PMC: 10926606. DOI: 10.1186/s12943-024-01938-8.

References

Schaefer W, Regula J, Bahner M, Schanzer J, Croasdale R, Durr H . Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011; 108(27):11187-92. PMC: 3131342. DOI: 10.1073/pnas.1019002108. View

Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017; 15(1):47-62. PMC: 6733403. DOI: 10.1038/nrclinonc.2017.148. View

Karches C, Benmebarek M, Schmidbauer M, Kurzay M, Klaus R, Geiger M . Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. Clin Cancer Res. 2019; 25(19):5890-5900. PMC: 7611266. DOI: 10.1158/1078-0432.CCR-18-3927. View

Minutolo N, Sharma P, Poussin M, Shaw L, Brown D, Hollander E . Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. J Am Chem Soc. 2020; 142(14):6554-6568. PMC: 7306176. DOI: 10.1021/jacs.9b11622. View

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius J, Sievers S . Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther. 2017; 25(11):2452-2465. PMC: 5675490. DOI: 10.1016/j.ymthe.2017.07.013. View

Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z . Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012; 18(23):6436-45. DOI: 10.1158/1078-0432.CCR-12-1449. View

Koristka S, Cartellieri M, Arndt C, Bippes C, Feldmann A, Michalk I . Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013; 42:105-16. DOI: 10.1016/j.jaut.2013.01.002. View

Vogler I, Newrzela S, Hartmann S, Schneider N, von Laer D, Koehl U . An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther. 2010; 18(7):1330-8. PMC: 2911262. DOI: 10.1038/mt.2010.83. View

Dundas C, DeMonte D, Park S . Streptavidin-biotin technology: improvements and innovations in chemical and biological applications. Appl Microbiol Biotechnol. 2013; 97(21):9343-53. DOI: 10.1007/s00253-013-5232-z. View

10.

Budde L, Berger C, Lin Y, Wang J, Lin X, Frayo S . Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. PMC: 3866194. DOI: 10.1371/journal.pone.0082742. View

11.

Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X . Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol. 2019; 10:2664. PMC: 6863137. DOI: 10.3389/fimmu.2019.02664. View

12.

Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D . FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Front Immunol. 2017; 8:457. PMC: 5406408. DOI: 10.3389/fimmu.2017.00457. View

13.

Wang X, Chang W, Wong C, Colcher D, Sherman M, Ostberg J . A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011; 118(5):1255-63. PMC: 3152493. DOI: 10.1182/blood-2011-02-337360. View

14.

Lanitis E, Poussin M, Klattenhoff A, Song D, Sandaltzopoulos R, June C . Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2014; 1(1):43-53. PMC: 3881605. DOI: 10.1158/2326-6066.CIR-13-0008. View

15.

Aalberse R, Schuurman J . IgG4 breaking the rules. Immunology. 2002; 105(1):9-19. PMC: 1782638. DOI: 10.1046/j.0019-2805.2001.01341.x. View

16.

Landgraf K, Williams S, Steiger D, Gebhart D, Lok S, Martin D . convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun Biol. 2020; 3(1):296. PMC: 7283332. DOI: 10.1038/s42003-020-1021-2. View

17.

Loureiro L, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C . Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018; 8(9):81. PMC: 6127150. DOI: 10.1038/s41408-018-0113-4. View

18.

Hanes J, Jermutus L, Bosshard H, Pluckthun A . Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci U S A. 1998; 95(24):14130-5. PMC: 24338. DOI: 10.1073/pnas.95.24.14130. View

19.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

20.

Lim K, Huang H, Pralle A, Park S . Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnol Bioeng. 2012; 110(1):57-67. DOI: 10.1002/bit.24605. View